Loading company…
Pharnext develops drug combinations for neurological diseases using genomic data and artificial intelligence.
Founded in 2007 and based in France, Pharnext is a biopharmaceutical company developing drug combinations for neurological diseases using genomic data and artificial intelligence. Its products include PLEODRUG PXT3003 for Charcot-Marie-Tooth disease type 1A and PLEODRUG PXT864 for Alzheimer's disease, Parkinson's disease, and ALS.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in